新华制药：获得富马酸伏诺拉生化学原料药上市申请批准

Core Viewpoint - The approval of fumaric acid volnorasone by the National Medical Products Administration enhances the company's product line and competitiveness, with potential sales in public medical institutions projected at approximately 825 million yuan in 2024 [1] Group 1: Product Approval - The company has received approval for fumaric acid volnorasone, which is primarily used for reflux esophagitis [1] - The application for market registration was submitted in March 2024 and has been accepted [1] Group 2: Market Potential - The product is classified as a Category B item in the medical insurance catalog, indicating its relevance in the healthcare market [1] - The estimated sales revenue for related formulations in Chinese public medical institutions is around 825 million yuan in 2024 [1] Group 3: Competitive Landscape - The approval is expected to enrich the company's product portfolio, thereby enhancing its competitive position in the pharmaceutical market [1] - However, the sales of the drug may be influenced by various factors, including policies and market conditions, leading to uncertainties [1]